Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | HCRTR2 | O43614 | 5/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14635889 | 0.95 | ALDH1A1 (0.53) | KMT2AALDH1A1HCRTR2HSD17B10HPGD | |
| SCHEMBL23793783 | 0.79 | KMT2A (0.46) | KMT2AALDH1A1HCRTR2HTTMTNR1A | |
| SCHEMBL19347965 | 0.79 | KMT2A (0.46) | KMT2AALDH1A1HCRTR2TSHRDPP4 | |
| SCHEMBL9728258 | 0.79 | ACE (0.53) | KMT2AALDH1A1HSD17B10 | |
| SCHEMBL14930583 | 0.79 | ALDH1A1 (0.50) | ALDH1A1HCRTR2HSD17B10HPGDGAA | |
| SCHEMBL7478058 | 0.79 | ALDH1A1 (0.50) | ALDH1A1HCRTR2HSD17B10HPGDGAA | |
| SCHEMBL10202307 | 0.79 | ALDH1A1 (0.50) | ALDH1A1HCRTR2HSD17B10HPGDGAA | |
| SCHEMBL28579495 | 0.77 | HRH3 (0.45) | KMT2AALDH1A1HCRTR2DPP4MAPK1 | |
| SCHEMBL20837322 | 0.77 | ALDH1A1 (0.49) | ALDH1A1HSD17B10HPGDGAATSHR | |
| SCHEMBL14291922 | 0.77 | ALDH1A1 (0.50) | ALDH1A1HCRTR2HSD17B10HPGDGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285570-A1 | THERAPEUTICALLY USEFUL CURE-PRO MOLECULES FOR E3 LIGASE MEDIATED DEGRADATION OF PROTEINS, AND METHODS OF MAKING AND USING THEM | CORNELL UNIVERSITY | 2023-09-14 | — | — | US | disclosed |
| US-20230277553-A1 | THERAPEUTIC COMPOSITION OF CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USAGE | CORNELL UNIVERSITY | 2023-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285570-A1 | THERAPEUTICALLY USEFUL CURE-PRO MOLECULES FOR E3 LIGASE MEDIATED DEGRADATION OF PROTEINS, AND METHODS OF MAKING AND USING THEM | XIAP, CUL4A, CUL1 | KMT2A 1372/4885ALDH1A1 2592/4885HCRTR2 4268/4885 |
| US-20230277553-A1 | THERAPEUTIC COMPOSITION OF CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USAGE | BET1, BRD4, PHKB | KMT2A 1071/4885ALDH1A1 4450/4885HCRTR2 3306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.